<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102071</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0262</org_study_id>
    <nct_id>NCT05102071</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas</brief_title>
  <official_title>Clinical and Economic Impact of 2nd Line Initiation of Empagliflozin After Metformin, as Compared to 2nd Line Initiation of Sulfonylurea After Metformin in Patients With Type 2 Diabetes and Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of clinical outcomes (specifically cardiovascular outcomes like hospitalization&#xD;
      for heart failure), and healthcare cost, and resource utilization, among patients on&#xD;
      empagliflozin as an add-on therapy to metformin versus patients on sulfonylureas as an add-on&#xD;
      therapy to metformin in patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of first hospitalization for congestive heart failure (HHF)</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency department (ED) visits</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of filled drugs</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient visits</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause cost</measure>
    <time_frame>up to 5 years and 3 months</time_frame>
    <description>total cost of care, divided by medical (inpatient costs, outpatient costs, emergency costs) and pharmacy costs (all reported in Per Patient Per Month (PPPM) costs)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment with empagliflozin</arm_group_label>
    <description>as add-on therapy with metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment with a sulfonylurea</arm_group_label>
    <description>as add-on therapy with metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>empagliflozin</description>
    <arm_group_label>Treatment with empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin</description>
    <arm_group_label>Treatment with a sulfonylurea</arm_group_label>
    <arm_group_label>Treatment with empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfonylurea</intervention_name>
    <description>sulfonylurea</description>
    <arm_group_label>Treatment with a sulfonylurea</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Prevalent metformin use + initiation of empagliflozin OR prevalent metformin use +&#xD;
             initiation of sulfonylurea&#xD;
&#xD;
          -  ≥18 years of age at index date during study observation&#xD;
&#xD;
          -  ≥1 inpatient and/or ≥ 2 outpatient claims denoting T2D diagnosis (in any position) in&#xD;
             the 12 months prior to index date&#xD;
&#xD;
          -  ≥1 inpatient and/or ≥2 outpatient claims denoting CVD (in any position) diagnosis in&#xD;
             the 12 months prior to index date&#xD;
&#xD;
          -  ≥2 months post-index date&#xD;
&#xD;
          -  ≥12 months of no exposure to T2D medications in the pre-index period (excluding&#xD;
             metformin in both arms)&#xD;
&#xD;
          -  ≥12 months of continuous enrolment prior to index date&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diagnosis of Type 1 Diabetes, secondary, or gestational diabetes in the 12 months&#xD;
             prior to index date&#xD;
&#xD;
          -  Diagnosis of severe comorbidities including malignancy, end-stage renal disease, human&#xD;
             immunodeficiency virus, Hepatitis C infection, or organ transplant in the 12 months&#xD;
             prior to index date&#xD;
&#xD;
          -  Admission to nursing home in the 12 months prior to index date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boehringer Ingelheim Pharmaceuticals Inc</name>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

